MedTrace Logo

Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine

NCT02773667 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2022-12-16

No results posted yet for this study

Summary

Correlation analysis between estimated renal function and biological half life of 131-I during radioiodine treatment of patients with differentiated thyroid cancer.

Conditions

  • Thyroid Carcinoma

Sponsors & Collaborators

  • Jena University Hospital

    lead OTHER

Principal Investigators

  • Martin Freesmeyer, Dr. med. · Study Principal Investigator

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02773667 on ClinicalTrials.gov